Protectan CBLB612: Phase I data

A single-blind, placebo-controlled Phase I trial in 56 healthy volunteers showed that single subcutaneous injections of 0.5-4 ug CBLB612 were generally well tolerated. The MTD was 4 ug CBLB612. CBLB61...